VCYT Q3 2021 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+94.0% YoY

Gross Profit

$39M64.1% margin

Operating Income

-$17M-27.6% margin

Net Income

-$14M-23.4% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+9.6%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$3M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$79M

Stockholders' Equity

$1.1B

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$31M	+94.0%
Gross Profit	$39M	$21M	+86.6%
Operating Income	-$17M	-$4M	-310.3%
Net Income	-$14M	-$4M	-242.6%

Revenue Segments

Testing

$16M63%

Biopharmaceutical And Other

$7M25%

Product

$3M12%